• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Immune response in patients with intraabdominal infections treated with imipenem. Swedish Study Group.

出版信息

Infection. 1989 Nov-Dec;17(6):369-73.

PMID:2693357
Abstract

In the present investigation the humoral immune response against isolated microorganisms in patients treated with imipenem was studied. Sixty-six patients (34 men and 32 women, 18-86 years of age) with suspicion of intraabdominal infections entered the study. Five patients were excluded for various reasons and the remaining 61 patients were treated with imipenem/cilastatin 0.5-1.0 g t.i.d. for 5-29 days (median nine days). Three serum samples were taken from each patient, the first sample at admission, the second between three and seven days after the first dose of imipenem/cilastatin and the third between 14 and 31 days after the first dose. One third of the patients had a malignant disease and the verified intraabdominal infections were judged to be severe in 23 and moderately severe in 33 of the patients. Fifty-six patients (92%) were cured and five patients (8%) were considered improved after the treatment. The immune response against isolated microorganisms was measured in the three serum samples by indirect immunofluorescence tests and enzyme-linked immunosorbent assays. Among the aerobic microorganisms isolated Escherichia coli (46 strains) Staphylococcus epidermidis (22 strains), Streptococcus milleri (15 strains) and Enterococcus faecalis (11 strains) dominated and among the anaerobic bacteria Bacteroides fragilis (39 strains). Thirty-two patients had significant immune responses against one or more of the isolated microorganisms. E. coli and B. fragilis gave rises in antibody titers in 13 and 20 cases respectively, while significant titers against S. epidermidis were noticed in only three cases, against S. milleri in two cases and against E. faecalis in three cases.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

相似文献

1
Immune response in patients with intraabdominal infections treated with imipenem. Swedish Study Group.
Infection. 1989 Nov-Dec;17(6):369-73.
2
Immune response in patients with intra-abdominal infections treated with carbapenems.接受碳青霉烯类药物治疗的腹腔内感染患者的免疫反应。
Int J Clin Pharmacol Res. 1994;14(3):111-4.
3
A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group.哌拉西林/他唑巴坦与亚胺培南/西司他丁治疗严重腹腔内感染的随机多中心试验。瑞典研究小组。
J Antimicrob Chemother. 1993 Jan;31 Suppl A:79-85. doi: 10.1093/jac/31.suppl_a.79.
4
Clinical evaluation of imipenem/cilastatin in the therapy of severe infections in high-risk patients.亚胺培南/西司他丁治疗高危患者严重感染的临床评估。
Drugs Exp Clin Res. 1989;15(1):17-20.
5
[Clinical experience with imipenem/cilastatin in the treatment of severe infections in general surgery].亚胺培南/西司他丁治疗普通外科严重感染的临床经验
Infection. 1986;14 Suppl 2:S160-3. doi: 10.1007/BF01647502.
6
Clinical evaluation of the imipenem/cilastatin combination in the therapy of severe infections in patients with malignant diseases.亚胺培南/西司他丁联合用药治疗恶性疾病患者严重感染的临床评价
Drugs Exp Clin Res. 1990;16(6):293-7.
7
Monobactams and carbapenems for treatment of intraabdominal infections.用于治疗腹腔内感染的单环β-内酰胺类抗生素和碳青霉烯类抗生素。
Infection. 1999 Mar-Apr;27(2):136-47. doi: 10.1007/BF02560517.
8
Imipenem/cilastatin in the treatment of intraabdominal infections: a review of worldwide experience.
Rev Infect Dis. 1985 Jul-Aug;7 Suppl 3:S518-21. doi: 10.1093/clinids/7.supplement_3.s518.
9
Results of a clinical trial of clinafloxacin versus imipenem/cilastatin for intraabdominal infections.环丙沙星与亚胺培南/西司他丁治疗腹腔内感染的临床试验结果。
Ann Surg. 2001 Jan;233(1):79-87. doi: 10.1097/00000658-200101000-00013.
10
Biapenem versus imipenem/cilastatin in the treatment of complicated intra-abdominal infections: report from a Swedish Study Group.比阿培南与亚胺培南/西司他丁治疗复杂性腹腔内感染:瑞典研究小组的报告
Scand J Infect Dis. 1996;28(5):507-12. doi: 10.3109/00365549609037949.

引用本文的文献

1
Imipenem/cilastatin: a pharmacoeconomic appraisal of its use in intra-abdominal infections.亚胺培南/西司他丁:对其用于腹腔内感染的药物经济学评估
Pharmacoeconomics. 1992 Jun;1(6):443-59. doi: 10.2165/00019053-199201060-00005.
2
Human immune response to an iron-repressible outer membrane protein of Bacteroides fragilis.人类对脆弱拟杆菌铁抑制性外膜蛋白的免疫反应。
Infect Immun. 1991 Sep;59(9):2999-3003. doi: 10.1128/iai.59.9.2999-3003.1991.

本文引用的文献

1
Infections following gastrointestinal surgery: intra-abdominal abscess.胃肠道手术后感染:腹腔内脓肿
Surg Clin North Am. 1980 Feb;60(1):197-212. doi: 10.1016/s0039-6109(16)42044-x.
2
The role of Bacteroides fragilis in the pathogenesis of acute appendicitis.脆弱拟杆菌在急性阑尾炎发病机制中的作用。
Acta Chir Scand. 1982;148(1):39-44.
3
Imipenem/cilastatin versus gentamicin/clindamycin for treatment of serious bacterial infections. Report from a Scandinavian Study Group.
Lancet. 1984 Apr 21;1(8382):868-71.
4
Imipenem/cilastatin in the treatment of intraabdominal infections: a review of worldwide experience.
Rev Infect Dis. 1985 Jul-Aug;7 Suppl 3:S518-21. doi: 10.1093/clinids/7.supplement_3.s518.
5
Therapeutic implications of bacteriologic findings in mixed aerobic-anaerobic infections.需氧菌与厌氧菌混合感染中细菌学检查结果的治疗意义
Antimicrob Agents Chemother. 1988 May;32(5):611-6. doi: 10.1128/AAC.32.5.611.
6
Occurrence and pathogenicity of the Streptococcus milleri group.米勒链球菌群的发生与致病性
Rev Infect Dis. 1988 Mar-Apr;10(2):257-85. doi: 10.1093/clinids/10.2.257.
7
Laboratory, clinical, and epidemiological aspects of coagulase-negative staphylococci.凝固酶阴性葡萄球菌的实验室、临床及流行病学特征
Clin Microbiol Rev. 1988 Jul;1(3):281-99. doi: 10.1128/CMR.1.3.281.